文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

撒哈拉以南非洲一线替诺福韦方案失败后隐匿性HIV-1胸苷类似物耐药的多中心回顾性队列研究

Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
PubMed 文献 · Lancet Infect Dis · 2016-12-01

该研究回顾性分析了撒哈拉以南非洲20项研究中712例一线替诺福韦+胞嘧啶类似物+奈韦拉平或依非韦伦方案病毒学失败的患者,发现16%存在至少一个胸苷类似物突变(TAM),且TAM与替诺福韦、NNRTI及胞嘧啶类似物耐药显著相关,提示TAM常见并关联多药耐药,需有效病毒载量监测和即时耐药检测。

要点

  • 一线替诺福韦方案失败患者中16%携带至少一个TAM。
  • TAM患者替诺福韦耐药率81% vs 59%,NNRTI耐药93% vs 77%。
  • TAM与多药耐药相关,应加强病毒载量监测和耐药检测。

核心结论

  • 在撒哈拉以南非洲一线含替诺福韦方案失败的患者中,胸苷类似物突变(TAM)常见,且与多药耐药HIV-1相关。

研究设计与样本

  • 回顾性多中心队列研究,分析TenoRes协作组20项研究中712例一线替诺福韦+胞嘧啶类似物+NNRTI方案病毒学失败的患者,基线访视于2005至2013年。

主要发现

  • 712例患者中115例(16%)至少有一个TAM。

临床怎么用

  • 对一线含替诺福韦方案病毒学失败的患者,应警惕TAM及多药耐药,加强病毒载量监测和耐药检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV-1 drug resistance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identified in sub-Saharan Africa in patients with virological failure of first-line combination antiretroviral therapy (ART) containing the modern nucleoside reverse transcriptase inhibitor tenofovir. We aimed to investigate the prevalence and correlates of thymidine analogue mutations (TAM) in patients with virological failure of first-line tenofovir-containing ART. METHODS: We retrospectively analysed patients from 20 studies within the TenoRes collaboration who had locally defined viral failure on first-line therapy with tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or efavirenz) in sub-Saharan Africa. Baseline visits in these studies occurred between 2005 and 2013. To assess between-study and within-study associations, we used meta-regression and meta-analyses to compare patients with and without TAMs for the presence of resistance to tenofovir, cytosine analogue, or NNRTIs. FINDINGS: Of 712 individuals with failure of first-line tenofovir-containing regimens, 115 (16%) had at least one TAM. In crude comparisons, patients with TAMs had lower CD4 counts at treatment initiation than did patients without TAMs (60·5 cells per μL [IQR 21·0-128·0] in patients with TAMS vs 95·0 cells per μL [37·0-177·0] in patients without TAMs; p=0·007) and were more likely to have tenofovir resistance (93 [81%] of 115 patients with TAMs vs 352 [59%] of 597 patients without TAMs; p<0·0001), NNRTI resistance (107 [93%] vs 462 [77%]; p<0·0001), and cytosine analogue resistance (100 [87%] vs 378 [63%]; p=0·0002). We detected associations between TAMs and drug resistance mutations both between and within studies; the correlation between the study-level proportion of patients with tenofovir resistance and TAMs was 0·64 (p<0·0001), and the odds ratio for tenofovir resistance comparing patients with and without TAMs was 1·29 (1·13-1·47; p<0·0001) INTERPRETATION: TAMs are common in patients who have failure of first-line tenofovir-containing regimens in sub-Saharan Africa, and are associated with multidrug resistant HIV-1. Effective viral load monitoring and point-of-care resistance tests could help to mitigate the emergence and spread of such strains. FUNDING: The Wellcome Trust.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gregson J, Kaleebu P, Marconi VC, et al. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infect Dis. 2016. PMID: 27914856. doi:10.1016/S1473-3099(16)30469-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。